Cancer Clinical Trials Information Platform in Hong Kong


  1. This serves merely as an information platform about cancer clinical trials operated by different institutions in Hong Kong. HKACS is not responsible for the contents, availability and operability of the trials listed.
  2. Respective institutions usually reserve all rights regarding the implementation and execution of their respective clinical trials.
  3. Patients usually need to satisfy a complex and stringent set of selection criteria before being selected/ included in certain clinical trials. Interested parties should contact respective institutions regarding further details of the trials


Cancer Site


*in alphabetical order (Last updated on 29/6/2022)


Others

Institution Study Title  
QMH Renal Cancer
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD- 1/L1 and VEGF-Targeted Therapies
Contact:
Ms.Carmen Chiu
22554915
QMH Renal Cancer
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk
Contact:
Ms. Irene Koo
2255 6220
HKU High-Grade Glioma
Combination Talazoparib - carboplatin for recurrent high-grade glioma with DNA damage repair deficiency (DDRd) “TAC-GReD” trial
Click for Details
CUHK Biliary Tract Cancer
(BTC007) A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
Click for Details
CUHK Biliary Tract Cancer
A Phase 3, Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine / Cisplatin versus Placebo Plus Gemcitabine / Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma
Click for Details
CUHK Biliary Tract Cancer
A Phase III Randomized, Double-Blind, Placebo-Controlled,Multi-Regional, International Study of Durvalumab in Combination withGemcitabine plus Cisplatin versus Placebo in Combination with Gemcitabine plusCisplatin for Patients with First-Line Advanced Biliary Tract Cancers (TOPAZ-1)
Click for Details
CUHK Endometrial Cancer
(GYE001) A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer – DUO-E
Click for Details
CUHK Cancer Pain
A pilot randomized open-labeled study comparing a structured titration method of immediate- and sustained-release oxycodone versus titration of investigators’ choice inadvanced cancer patients in Hong Kong
Click for Details


For Enquiry, please contact the respective institute, HKACS is not responsible for the outcomes of the clinical trials.